Largest study of hemodynamically supported high-risk pci patients finds more complete revascularization with impella leads to improved outcomes

Danvers, mass.--(business wire)--abiomed (nasdaq: abmd) announces new protect iii study data that demonstrates reduced rates of macce (composite of death, stroke, myocardial infarction and repeat procedures) when impella is used to achieve a more complete revascularization in a single setting for high-risk percutaneous coronary intervention (pci) patients. protect iii is an ongoing, prospective, single-arm fda post-approval study for the pma approval of impella 2.5 and impella cp in high-risk p
ABMD Ratings Summary
ABMD Quant Ranking